GlucoTrack, Inc. (GCTK) Stock Score, Valuation & Financial Research

GlucoTrack, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GCTK

GlucoTrack, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.64. These figures are a research snapshot, not a buy or sell recommendation.

What GlucoTrack, Inc. does

GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Glucotrack, Inc. is a medical technology company currently in the research and development stage, focused on creating an implantable continuous blood glucose monitoring system. The company does not currently generate revenue from product sales and relies on capital raises and financing activities to fund its ongoing operations and clinical development programs.

Products and services

  • The company is developing an implantable continuous blood glucose monitoring (CBGM) system for individuals with Type 1 and Type 2 diabetes. It has discontinued its previous non-invasive glucose monitoring device.

Brands and product families

  • Glucotrack — The primary brand associated with the company's implantable CBGM development program. Source

Customer types

People with Type 1 diabetes; People with Type 2 diabetes using insulin.

Suppliers, materials and equipment

  • Contract Manufacturers — The company utilizes third-party contract manufacturers for the development and production of its medical device components. Source

Competitors and product-market comparisons

  • Dexcom, Inc. — Developer of continuous glucose monitoring systems. Source
  • Abbott Laboratories — Developer of continuous glucose monitoring systems. Source
  • Medtronic plc — Developer of continuous glucose monitoring systems. Source

Business strengths to evaluate

  • Intellectual property portfolio related to CBGM technology Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on successful clinical trials and regulatory approval Source
  • Need for additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GCTK financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.64
Market capitalization:
1.31M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -15.95M
Free cash flow:
USD -15.34M
Cash:
USD 1.12M
Total debt:
USD 19K
EPS:
USD -180.45

What stands out

  • Free cash flow is USD -15.34M, negative for the stored period.
  • The balance sheet shows USD 1.12M of cash versus USD 19K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.11M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GCTK

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GCTK fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GCTK likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GCTK to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GCTK's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GCTK

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.